The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels
MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year,
GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.
A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.
AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for.
Its first-quarter
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844